Mouse model demonstrates mutation effects on hematopoiesis and myelopoiesis in myeloid malignancy, suggesting new insights into MDS and AML progression.
Key Points
This research aims to examine the role of U2AF1 and TET2 mutations in myeloid malignancies using mouse models.
Used U2AF1 S34F mouse model with Mx1Cre activation following poly(I:C) treatment
Crossed U2AF1 S34F transgene into HSC-SCL Cre-ER mice activated by tamoxifen
Analyzed blood counts and flow cytometry data over 14 weeks
Compared wild-type, U2AF1 heterozygous, TET2 knockout, and double mutant mice
Increased MCV in U2AF1 heterozygous and double mutant mice at 10 and 14 weeks, indicating MDS traits
Decreased myelopoiesis observed in peripheral blood of U2AF1 heterozygous and double mutant mice
No significant changes in bone marrow myeloid populations, suggesting a specific impact on terminal differentiation
Retention of mutant U2AF1 cells confirmed throughout the study